Search results
Results From The WOW.Com Content Network
Doxorubicin, sold under the brand name Adriamycin among others, is a chemotherapy medication used to treat cancer. [10] This includes breast cancer, bladder cancer, Kaposi's sarcoma, lymphoma, and acute lymphocytic leukemia. [10] It is often used together with other chemotherapy agents. [10] Doxorubicin is given by injection into a vein. [10]
The occurrence of adriamycin-related cardiac toxicity is related to the total lifetime dose of adriamycin, and increases sharply in people who receive a cumulative dose of more than 400 mg/m 2. Almost all patients treated with ABVD receive less than this dose (for 6 cycles of ABVD, the cumulative adriamycin dose is 300 mg/m 2 ); therefore ...
The term 'hyper' refers to the hyperfractionated nature of the chemotherapy, which is given in smaller doses, more frequently, to minimize side effects. 'CVAD' is the acronym of the drugs used in course A: cyclophosphamide, vincristine, doxorubicin (also known by its trade name, Adriamycin), and dexamethasone.
Radiolabelled doxorubicin has been utilised as a breast cancer lesion imaging agent in a pilot study. This radiochemical, 99m Tc-doxorubicin, localised to mammary tumour lesions in female patients, and is a potential radiopharmaceutical for imaging of breast tumours. [41]
Doxorubicin (trade name Adriamycin) or hydroxyldaunorubicin is a DNA-interacting drug widely used in chemotherapy. It is an anthracycline antibiotic and structurely closely related to daunomycin, and also intercalates DNA. It is commonly used in the treatment of a wide range of cancers.
Infusion of R,C,H and O components of R-CHOP. Red flask contains doxorubicin (H), the most toxic component. Prednisolone (P) is administered on the next four or five days intravenously or in tablets. [1] CHOP is the acronym for a chemotherapy regimen used in the treatment of non-Hodgkin lymphoma. CHOP consists of:
A chemotherapy regimen is a regimen for chemotherapy, defining the drugs to be used, their dosage, the frequency and duration of treatments, and other considerations.In modern oncology, many regimens combine several chemotherapy drugs in combination chemotherapy.
By conducting a meta-analysis of four large breast cancer trials including nearly 3,000 patients, the researchers have discovered that an abnormality on chromosome 17, called CEP17, is associated with a worse outcome for patients, but also that its presence is a highly significant indicator that the tumor will respond to anthracyclines.